Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination

Chen, Xiuju; Wang, Bin; Li, Xiaoxin

doi:10.1016/j.ajoc.2022.101404

Cited by 20 publications

(11 citation statements)

References 22 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previously healthy 36-year-old female presented to the retina clinic with sudden painless vision loss in her left eye one week after receiving the first inactivated COVID-19 [ 12 ] vaccine (Sinopharm). She had also experienced mild flu-like symptoms 3 days after the vaccination.…”

Section: Resultsmentioning

confidence: 99%

“…VKH or VKH-like disease has previously been reported with inactivated vaccines against yellow fever, influenza, and HPV, which may have been induced by the adjuvants [ 20 , 21 ]. While there are reported new onset and reactivation of VKH disease related to the Pfizer mRNA vaccine, in view of the similar phenotype of uveitis despite a different type of vaccine, the antigen mimicry from the virus instead could be a potential trigger [ 12 , 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Chen

et al. 2022

Vaccines

Self Cite

View full text Add to dashboard Cite

Aims: To report potential vaccine-induced ocular adverse events following inactivated COVID-19 vaccination (Sinopharm and Sinovac). Methods: This case series took place at a tertiary referral center in the southeast of China (Xiamen Eye Center in Fujian Province) from February 2021 to July 2021. Patients who received the first dose of inactivated COVID-19 vaccine and developed vaccine-related ocular adverse events within 10 days were included. The diagnosis of vaccine-related ocular adverse events was guided by the World Health Organization causality assessment and the Naranjo criteria. Results: Ten eyes of seven patients (two male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30–55 years). The mean time of ocular adverse event manifestations was 4.9 days (range, 1–10 days). Three patients were diagnosed with Vogt–Koyanagi–Harada (VKH)-like uveitis, one with multifocal choroiditis, one with episcleritis, one with iritis, and one with acute idiopathic maculopathy. Two patients received the second dose of vaccine. One patient had exacerbation of VKH, and one patient had no symptoms. An aqueous humor analysis in three patients revealed elevated proinflammatory cytokines and negative virus copy. All the patients had transient ocular disturbance and responded well to steroids. No recurrence was noted during 6 months of follow-up. Conclusions: Potential ocular adverse events should be reported to increase the awareness of the health community for timely detection and proper treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Chen

et al. 2022

Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

“…There were several case reports on inactivated COVID-19 vaccines BBIBP-CorV or Corona Vac-associated uveitis and other ocular complications. 5 , 8–10 , 12 , 13 However, it is not known whether the three types of COVID-19 vaccines have significant difference in safety, particularly in relation to ocular health.…”

Section: Discussionmentioning

confidence: 99%

“… 4–11 There are also several previous reports about inactivated COVID-19 vaccine associated uveitis and other ocular complications. 5 , 8–10 , 12 , 13 Most of them are case reports. Here, we report a case series of ocular inflammatory events associated with the administration of inactivated COVID-19 vaccination without previous ocular inflammatory history.…”

Section: Introductionmentioning

confidence: 99%

Inflammatory ocular events after inactivated COVID-19 vaccination

Fei

Feng

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

To report potential vaccine-induced inflammatory ocular adverse events following inactivated COVID-19 vaccination. Retrospective study of patients with uveitis and other ocular complications following inactivated coronavirus disease 2019 (COVID-19) vaccination at a tertiary referral center between May 2021 and August 2021. Data collection consisted of demographic and clinical data. The study included 8 eyes of 5 patients (4 females, 1 male), with a mean age of 37.2 ± 12.5 years (range 28–59 years). Mean time between vaccination and ocular complications onset was 13.2 ± 11.9 days (range 3–30 days), including two patients after the first dose of the vaccine and 3 patients after the second dose. The cases reported were three anterior uveitis, one herpetic keratitis and iridocyclitis, and one posterior uveitis. Patients received treatment with local and/or systemic steroids and all the patients had good visual outcomes. Ocular inflammatory events may occur after vaccination with possible gender preponderance. However, they are rare and manageable. Overall, the efficacy and safety of vaccination should be emphasized.

show abstract

Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination

Cited by 20 publications

References 22 publications

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

Inflammatory ocular events after inactivated COVID-19 vaccination

Contact Info

Product

Resources

About